Genedrive PLC
Genedrive operates with a fully diluted share count of 1,605,568,256 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Genedrive, as the valuation snapshot does not include key performance indicators such as ROIC, EBITDA margins, or net profit margins. This lack of data prevents a direct comparison to industry_config preferred metrics or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with over-reliance on specific markets or customer segments. Genedrive's growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or revenue history. This absence of forward-looking guidance limits the ability to evaluate the company's growth potential. Risk factors include the inability to assess liquidity risk, which could impact
Business. Genedrive PLC (GDRG.L) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Genedrive PLC (GDRG.L) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Genedrive operates with a fully diluted share count of 1,605,568,256 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available for Genedrive, as the valuation snapshot does not include key performance indicators such as ROIC, EBITDA margins, or net profit margins. This lack of data prevents a direct comparison to industry_config preferred metrics or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with over-reliance on specific markets or customer segments.
Genedrive's growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or revenue history. This absence of forward-looking guidance limits the ability to evaluate the company's growth potential.
Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the lack of financial transparency may obscure potential dilution sources.
Recent events, such as filings or transcripts, are not available in the provided data, which limits the ability to evaluate the company's strategic direction or operational developments.
- Genedrive operates in the Advanced Medical Equipment & Technology industry with a high classification confidence.
- The company has no difference between basic and diluted shares, indicating no immediate dilution risk.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
- Profitability and growth metrics are not available, limiting the ability to evaluate performance against industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, making it difficult to assess market risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue £55.0k, +12,2% YoY; Operating income +7,0% YoY.
- ▍Revenue £55.0k, +12,2% YoY
- ▍Operating income +7,0% YoY
- ▍Net income −10,2% YoY
- ▍Free cash flow −10,3% YoY
- ▍Net margin -9363.6%
Revenue £49.0k, −92,9% YoY; Operating income −2,4% YoY.
- ▍Revenue £49.0k, −92,9% YoY
- ▍Operating income −2,4% YoY
- ▍Net income −576,6% YoY
- ▍Free cash flow −717,3% YoY
- ▍Net margin -9540.8%
Revenue £687.0k; Operating income -£5.5M.
- ▍Revenue £687.0k
- ▍Operating income -£5.5M
- ▍Net margin -100.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Genedrive PLC Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Gino MieleChief Executive Officer, Executive Director